BR0214344A - 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 - Google Patents
11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1Info
- Publication number
- BR0214344A BR0214344A BR0214344-5A BR0214344A BR0214344A BR 0214344 A BR0214344 A BR 0214344A BR 0214344 A BR0214344 A BR 0214344A BR 0214344 A BR0214344 A BR 0214344A
- Authority
- BR
- Brazil
- Prior art keywords
- beta
- hydroxy steroid
- compounds
- formula
- steroid dehydrogenase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Abstract
"INIBIDORES DE 11 - BETA - HIDROXI ESTERóIDE DESIDROGENASE TIPO 1". A presente invenção se refere a compostos com a fórmula (I): em que os substituintes T, R^ 1^, B~ 1~, B~ 2~ e B~ 3~ são como definidos no relatório descritivo e/ou no quadro reivindicatório do presente pedido de patente. A presente invenção também se refere às composições farmacêuticas compreendendo os compostos de fórmula (I), bem como à utilização dos compostos de fórmula (I) em medicina e à utilização dos compostos de fórmula (I) para a preparação de um medicamento que atua sobre a enzima 11-<225>-hidroxiesteróide desidrogenase tipo 1 humana (11<225>HSD1)."11 - BETA - HYDROXY STEROID DEHYDROGENASE TYPE 1 INHIBITORS". The present invention relates to compounds of formula (I): wherein the substituents T, R1, R1, B1, B2 and B3 are as defined in the specification and / or table. of the present patent application. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I) as well as the use of the compounds of formula (I) in medicine and the use of the compounds of formula (I) for the preparation of a medicament acting on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11β HSD1).
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0103915 | 2001-11-22 | ||
SE0103913 | 2001-11-22 | ||
SE0104051 | 2001-11-30 | ||
US34834002P | 2002-01-14 | 2002-01-14 | |
US34846802P | 2002-01-14 | 2002-01-14 | |
PCT/SE2002/002138 WO2003044009A1 (en) | 2001-11-22 | 2002-11-22 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0214344A true BR0214344A (en) | 2004-09-14 |
Family
ID=27532726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0214344-5A BR0214344A (en) | 2001-11-22 | 2002-11-22 | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1461333A1 (en) |
JP (1) | JP2005509677A (en) |
KR (1) | KR20050044517A (en) |
CN (1) | CN1633428A (en) |
AU (1) | AU2002353716A1 (en) |
BR (1) | BR0214344A (en) |
CA (1) | CA2466733A1 (en) |
IL (1) | IL160648A0 (en) |
MX (1) | MXPA04004837A (en) |
PL (1) | PL370275A1 (en) |
WO (1) | WO2003044009A1 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521431B2 (en) | 2002-11-01 | 2009-04-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1 |
SE0301888D0 (en) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
EP1675844A1 (en) * | 2003-10-23 | 2006-07-05 | Sterix Limited | Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase |
GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
CA2548309A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
JP2007532659A (en) * | 2004-04-14 | 2007-11-15 | アムゲン インコーポレイティッド | Aryl sulfones and related uses |
JP2007533749A (en) | 2004-04-20 | 2007-11-22 | アムゲン インコーポレイティッド | Arylsulfonamides and related methods of use |
GB0408771D0 (en) * | 2004-04-20 | 2004-05-26 | Sterix Ltd | Compound |
ES2318503T3 (en) | 2004-05-24 | 2009-05-01 | Amgen Inc. | INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1. |
US8686011B2 (en) | 2004-05-24 | 2014-04-01 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
ES2309789T3 (en) | 2004-07-28 | 2008-12-16 | F. Hoffmann-La Roche Ag | ARIL-PIRIDINE DERIVATIVES AS INHIBITORS OF 11-BETA-HSD1. |
AU2005291561B2 (en) * | 2004-10-04 | 2010-02-25 | F. Hoffmann-La Roche Ag | Alkil-pyridines as 11-beta inhibitors for diabetes |
EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
US7759339B2 (en) | 2005-03-31 | 2010-07-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
CA2602781C (en) | 2005-04-05 | 2011-02-08 | F. Hoffmann-La Roche Ag | 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase |
EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
CA2624831A1 (en) * | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
EP1951696A2 (en) | 2005-11-22 | 2008-08-06 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
GB0526255D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JP5068768B2 (en) | 2006-01-18 | 2012-11-07 | エフ.ホフマン−ラ ロシュ アーゲー | Thiazole as an 11 beta-HSD1 inhibitor |
WO2007092435A2 (en) | 2006-02-07 | 2007-08-16 | Wyeth | 11-beta hsd1 inhibitors |
PE20110235A1 (en) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE |
EP2061767B1 (en) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
JP5361857B2 (en) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | Ion channel inhibitors |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
GB0804685D0 (en) | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
AR072707A1 (en) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
RU2012111354A (en) | 2009-08-26 | 2013-10-10 | Санофи | NEW CRYSTALLINE HYDRATES OF FLUORGYCLOSIDES CONTAINING THEIR PHARMACEUTICAL DRUGS AND THEIR USE |
ES2540547T3 (en) * | 2009-09-16 | 2015-07-10 | The University Of Edinburgh | Compounds of (4-phenyl-piperidin-1-yl) - [5- (1H-pyrazol-4-yl) -thiophene-3-yl] -methanone and its use |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
EP2563780B1 (en) | 2010-04-29 | 2015-05-06 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1 |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
WO2012120050A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683698B1 (en) | 2011-03-08 | 2017-10-04 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683703B1 (en) | 2011-03-08 | 2015-05-27 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683705B1 (en) | 2011-03-08 | 2015-04-22 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
TW201512171A (en) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | Chemical compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB822947A (en) * | 1957-01-25 | 1959-11-04 | Smith & Nephew | Improvements in and relating to sulphonamides |
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
IL129148A0 (en) * | 1996-10-16 | 2000-02-17 | American Cyanamid Co | The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
CZ302691B6 (en) * | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-arylamide compound, process for its preparation, pharmaceutical composition containing thereof, the compound for use as activator and for use in therapy or prophylaxis |
AU2002213048A1 (en) * | 2000-10-05 | 2002-04-15 | Smith Kline Beecham Corporation | Phosphate transport inhibitors |
-
2002
- 2002-11-22 JP JP2003545646A patent/JP2005509677A/en active Pending
- 2002-11-22 CN CNA028202503A patent/CN1633428A/en active Pending
- 2002-11-22 WO PCT/SE2002/002138 patent/WO2003044009A1/en active Application Filing
- 2002-11-22 IL IL16064802A patent/IL160648A0/en unknown
- 2002-11-22 MX MXPA04004837A patent/MXPA04004837A/en unknown
- 2002-11-22 PL PL02370275A patent/PL370275A1/en unknown
- 2002-11-22 AU AU2002353716A patent/AU2002353716A1/en not_active Abandoned
- 2002-11-22 EP EP02789088A patent/EP1461333A1/en not_active Withdrawn
- 2002-11-22 CA CA002466733A patent/CA2466733A1/en not_active Abandoned
- 2002-11-22 BR BR0214344-5A patent/BR0214344A/en not_active Application Discontinuation
- 2002-11-22 KR KR1020047007553A patent/KR20050044517A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2005509677A (en) | 2005-04-14 |
PL370275A1 (en) | 2005-05-16 |
IL160648A0 (en) | 2004-07-25 |
CN1633428A (en) | 2005-06-29 |
CA2466733A1 (en) | 2003-05-30 |
AU2002353716A1 (en) | 2003-06-10 |
EP1461333A1 (en) | 2004-09-29 |
WO2003044009A1 (en) | 2003-05-30 |
KR20050044517A (en) | 2005-05-12 |
MXPA04004837A (en) | 2004-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214344A (en) | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 | |
BR0214342A (en) | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 | |
NO20042596L (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
BRPI0510394A (en) | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
SE0001899D0 (en) | New compounds | |
BR0212378A (en) | 17betahydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
BRPI0513184A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation and application thereof in therapy | |
DK1487829T3 (en) | Thiadizolylpiperazine derivatives useful for treating or preventing pain | |
TR201820559T4 (en) | Compositions containing Azelastine and methods of use. | |
BRPI0316264B8 (en) | compounds, their use and pharmaceutical formulation containing them | |
BRPI0108395B8 (en) | pyrrolopyrimidinone derivatives, preparation and use processes | |
WO2005075471A3 (en) | Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
BRPI0517792A (en) | macrolones - amino substituted quinolones | |
BRPI0513744A (en) | guanidine derivatives and their therapeutic uses | |
BRPI0510849A (en) | dpp-iv inhibitor compounds, pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical composition comprising them and use of said compounds in the manufacture of medicament | |
ES2187300A1 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | |
BR0314898A (en) | Compounds, cosmetic composition, cosmetic use of a composition, use of a compound and pharmaceutical composition | |
BRPI0417833A (en) | benzofuran derivatives which may be used for the prophylaxis or treatment of 5-ht6 receptor-related disorders | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
SE0302573D0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0301701D0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE9904421D0 (en) | New compounds | |
BRPI0407968A (en) | oxamide derivatives useful as raf kinase inhibitors | |
SE0301699D0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0302570D0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |